Avenue Therapeutics Pain Management Treatment Rejected By FDA Again; Shares Drop
Avenue Therapeutics Inc (NASDAQ:ATXI) has received a second Complete Response Letter from the FDA regarding its marketing application seeking approval for…
Sorrento Therapeutics Starts Large Efficacy Trial For Intranasal COVID-19 Antibody In UK
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) signed off Sorrento Therapeutics Inc’s (NASDAQ:SRNE) Phase 2 trial evaluating COVI-DROPS in…
G1 Therapeutics Initiates PRESERVE 3, A Randomized Phase 2 Study Of COSELA In Bladder Cancer
G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that the Company has initiated PRESERVE 3, a Phase 2, randomized, open-label study of COSELA™ (trilaciclib) administered
Landos Biopharma Announces Outcome Of End-Of-Phase 2 Meeting With FDA For Omilancor In Mild-To-Moderate Active Ulcerative Colitis; Co. And FDA Agreed On Key Elements Necessary For Approval
Landos Biopharma, Inc. (NASDAQ:LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE Advanced Artificial Intelligence (A.I.) platform to discover and develop novel oral therapeutics for patients with
Avenue Therapeutics Receives Complete Response Letter From FDA For IV Tramadol; CRL States That ‘the delayed and unpredictable onset of analgesia with IV tramadol does not support its benefit as a monotherapy to treat patients in acute pain’
Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, today announced that it has received a second Complete
Anavex Life Sciences Highlights Publication In Medical Journal Elucidating the Mechanism of ANAVEX2-73 And ANAVEX3-71 Related To The Treatment Of Alzheimer’s Disease
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and
Long-awaited Novavax’s COVID-19 Vaccine Results Hit 90% Efficacy In Pivotal US Trial, 100% Efficacy Against Moderate, Severe Infection
Novavax Inc (NASDAQ:NVAX) has finally completed its U.S. Phase 3 trial for its protein-based COVID-19 vaccine candidate. Overall efficacy in the…
Novavax’s COVID-19 Vaccine Candidate Showed Immune Response, Protection Against Variants
Novavax Inc (NASDAQ:NVAX) announced preclinical and clinical data on its recombinant protein COVID-19 vaccine candidate, NVX-CoV2373, directed against the SARS-CoV-2 Beta…
Novavax Announces Co.’s COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
Novavax, Inc. (NASDAQ:NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and
The Week Ahead In Biotech: Takeda, Blueprint Medicines, Orphazyme, Eton On The Radar Ahead Of FDA Decisions, IPOs
Biotech stocks extended their gains in the week ended June 11, supported by the broader market strength and some stock-specific moves.